Home » Newsletters » BioWorld Science

BioWorld Science

July 17, 2014

View Archived Issues

Mymetics to manufacture Imugene's HER-Vaxx cancer immunotherapy

Medigene completes capital increase to fund cancer immunotherapy programs

Immatics biotechnologies receives final tranche of series D financing

C2N expands partnership with WUSM for Alzheimer's blood test

La Jolla Pharmaceutical's LJPC-1010 shows promise in preclinical model of NASH

Lilly discloses new anti-BMP-6 MAbs

Daiichi Sankyo to begin several trials of DS-5565 for pain associated with fibromyalgia

Novartis patents new modified IGF-I polypeptides

New disulfide-linked multivalent multi-function proteins divulged by Roche

Merck & Co. synthesizes novel glucokinase activators

Novel gamma-secretase modulators synthesized by Janssen Pharmaceutica

CSF proteins as potential markers of pediatric CNS tumors

Novel CFTR channel inhibitors patented by Novartis

Researchers from Lexicon present promising data for LX-4211 in humans and mice

Actinium Pharmaceuticals begins development of new actinium-225-labeled antibody construct

Researchers in France divulge new agents for mycobacterial infections

FDA lifts partial clinical hold on CTP-354

SUVN-A60203 counteracts cognitive defects associated with neuropathic pain

Epirus Biopharmaceuticals and Zalicus complete merger

Nintedanib receives breakthrough therapy designation for idiopathic pulmonary fibrosis

InnoPharma acquired by Pfizer

Isavuconazole receives another QIDP designation from FDA

BioLineRx reports data from phase I/II study of BL-7010 in celiac disease

FDA approves Ruconest for acute angioedema attacks

Lorus Therapeutics proposes name change

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
In the clinic for April 21, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Abbott, Agenus, Astrazeneca, Briacell, Clearmind, Greenwich, Intodna,...